Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

Leukemia

Volumn 29, Issue 5, 2015, Pages 1143-1152

  Crucitti, L ^a   Crocchiolo, R ^b   Toffalori, C ^a   Mazzi, B ^a   Greco, R ^a   Signori, A ^c   Sizzano, F ^a   Chiesa, L ^a   Zino, E ^a   Lupo Stanghellini, M T ^a   Assanelli, A ^a   Carrabba, M G ^a   Marktel, S ^a   Marcatti, M ^a   Bordignon, C ^d,e   Corti, C ^a   Bernardi, M ^a   Peccatori, J ^a   Bonini, C ^a   Fleischhauer, K ^a,f   Ciceri, F ^a   Vago, L ^a   more..

^a SAN RAFFAELE HOSPITAL   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e MOLMED S P A   (Italy)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; IMMUNOLOGIC FACTOR; LEUKOCYTE ANTIGEN; MELPHALAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; RAPAMYCIN; RITUXIMAB; THIOTEPA; THYMOCYTE ANTIBODY; HLA ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOIMMUNITY; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE ACTIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEREDITY; HLA SYSTEM; HUMAN; IMMUNOGENETICS; LEUKEMIA; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK FACTOR; SCREENING; T LYMPHOCYTE; UNRELATED DONORS; WHOLE BODY RADIATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84929280131     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.314     Document Type: Article

References (33)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
2. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-1907.
3. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371-4383.
4. Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 2010; 16: 871-890.
5. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101.
6. Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. Biol Blood Marrow Transplant 2013; 19: 1537-1545.
7. Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009; 361: 478-488.
8. Vago L, Toffalori C, Ciceri F, Fleischhauer K. Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-ver-sus-leukemia. Semin Oncol 2012; 39: 707-715.
9. Villalobos IB, Takahashi Y, Akatsuka Y, Muramatsu H, Nishio N, Hama A et al. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. Blood 2010; 115: 3158-3161.
10. Waterhouse M, Pfeifer D, Pantic M, Emmerich F, Bertz H, Finke J. Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1450-1459 e1451.
11. Toffalori C, Cavattoni I, Deola S, Mastaglio S, Giglio F, Mazzi B et al. Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT. Blood 2012; 119: 4813-4815.
12. Tamaki H, Fujioka T, Ikegame K, Yoshihara S, Kaida K, Taniguchi K et al. Different mechanisms causing loss of mismatched human leukocyte antigens in relapsing t (6;11)(q27;q23) acute myeloid leukemia after haploidentical transplantation. Eur J Haematol 2012; 89: 497-500.
13. Dubois V, Sloan-Bena F, Cesbron A, Hepkema BG, Gagne K, Gimelli S et al. Pretransplant HLA mistyping in diagnostic samples of acute myeloid leukemia patients due to acquired uniparental disomy. Leukemia 2012; 26: 2079-2085.
14. Smith AG, Fan W, Regen L, Warnock S, Sprague M, Williams R et al. Somatic mutations in the HLA genes of patients with hematological malignancy. Tissue Antigens 2012; 79: 359-366.
15. Coppage M, Iqbal A, Ahmad A, Becker MW. Leukemia specific loss of heterozygosity of MHC in a CLL patient: disease state impacts timing of confirmatory typing. Hum Immunol 2013; 74: 41-44.
16. Masuda K, Hiraki A, Fujii N, Watanabe T, Tanaka M, Matsue K et al. Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci 2007; 98: 102-108.
17. Gupta M, Raghavan M, Gale RE, Chelala C, Allen C, Molloy G et al. Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer 2008; 47: 729-739.
18. Raghavan M, Smith LL, Lillington DM, Chaplin T, Kakkas I, Molloy G et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 2008; 112: 814-821.
19. van Rood JJ, Roelen DL, Claas FH. The effect of noninherited maternal antigens in allogeneic transplantation. Semin Hematol 2005; 42: 104-111.
20. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
21. Apperley J, Carreras E, Gluckman E, Masszi T ESH-EBMT Handbook on Haematopoietic Stem Cell Transplantation, Forum Service Editore: Genova, Italy, 2012.
22. Mazzi B, Clerici TD, Zanussi M, Lupo Stanghellini MT, Vago L, Sironi E et al. Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. Leukemia 2008; 22: 2119-2122.
23. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489-500.
24. Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2015; 29: 396-405.
25. Luznik L, O'Donnell PV, Fuchs EJ. Posttransplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 2012; 39: 683-693.
26. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013; 119: 978-985.
27. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121: 849-857.
28. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.
29. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012; 47: 906-923.
30. Petersdorf EW. Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol 2008; 20: 588-593.
31. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
32. Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:5580-5586.
33. Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM et al. Agedependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol 2012; 91: 9-18.